Recent key advances in human immunodeficiency virus medicine and implications for China
- PMID: 20500898
- PMCID: PMC2890503
- DOI: 10.1186/1742-6405-7-12
Recent key advances in human immunodeficiency virus medicine and implications for China
Abstract
In this article we summarize several recent major developments in human immunodeficiency virus treatment, prevention, outcome, and social policy change. Updated international guidelines endorse more aggressive treatment strategies and safer antiretroviral drugs. New antiretroviral options are being tested. Important lessons were learned in the areas of human immunodeficiency virus vaccines and microbicide gels from clinical studies, and additional trials in prevention, especially pre-exposure prophylaxis, are nearing completion. Insight into the role of the virus in the pathogenesis of diseases traditionally thought to be unrelated to acquired immunodeficiency syndrome has become a driving force for earlier and universal therapy. Lastly, we review important achievements of and future challenges facing China as she steps into her eighth year of the National Free Antiretroviral Treatment Program.
Similar articles
-
Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.J Virol. 2016 May 12;90(11):5315-5328. doi: 10.1128/JVI.00230-16. Print 2016 Jun 1. J Virol. 2016. PMID: 27009957 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges.Curr HIV/AIDS Rep. 2020 Feb;17(1):26-34. doi: 10.1007/s11904-019-00478-x. Curr HIV/AIDS Rep. 2020. PMID: 31939111 Free PMC article. Review.
-
[Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].Enferm Infecc Microbiol Clin. 2000 Aug-Sep;18(7):329-51. Enferm Infecc Microbiol Clin. 2000. PMID: 11109725 Spanish.
-
Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.Int J Clin Pharm. 2014 Feb;36(1):70-85. doi: 10.1007/s11096-013-9861-1. Epub 2013 Oct 16. Int J Clin Pharm. 2014. PMID: 24129582 Free PMC article. Review.
Cited by
-
Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens.Medicine (Baltimore). 2015 Oct;94(42):e1677. doi: 10.1097/MD.0000000000001677. Medicine (Baltimore). 2015. PMID: 26496277 Free PMC article.
-
Needle and syringe programs in Yunnan, China yield health and financial return.BMC Public Health. 2011 Apr 21;11:250. doi: 10.1186/1471-2458-11-250. BMC Public Health. 2011. PMID: 21507267 Free PMC article.
References
-
- U.S. Food and Drug Administration. Antiretroviral Drugs Used in the Treatment of HIV Infection. http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/hivandaid...
-
- Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860. doi: 10.1056/NEJM199803263381301. - DOI - PubMed
-
- U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
-
- World Health Organization (WHO). New HIV recommendations to improve health, reduce infections and save lives World AIDS Day 2009. http://www.who.int/mediacentre/news/releases/2009/world_aids_20091130/en...
LinkOut - more resources
Full Text Sources
Molecular Biology Databases